Providing antiviral medications to healthcare workers immediately after exposure to orthoebolavirus reduces worker deaths by sixty-four percent. People usually assume that clinical staff have no medical defense after virus exposure until active symptoms appear or vaccines arrive. Post-exposure pills block the virus from multiplying inside human tissue before an infection takes hold.
When a protective suit tears or infected bodily fluid splashes onto skin, viral particles enter host cells to duplicate. Antiviral molecules bind to viral enzymes inside those cells, acting like a chemical brake on an engine. Halting this replication prevents the viral load from expanding throughout the bloodstream and damaging internal organs. Administering doses on the day of exposure keeps the initial viral population small enough for natural defenses to clear.
Researchers calibrated a transmission model using data from the 2013 west Africa epidemic and the 2018 outbreak in eastern DR Congo. They simulated how eighty percent drug efficacy and eighty percent distribution coverage changed cumulative deaths among frontline staff. In simulated west African conditions, worker fatalities dropped from 553 down to 200, while targeted high-risk delivery required forty-four doses per life saved.
Public health agencies can now plan rapid antiviral deployment to protect emergency medical teams when species-specific vaccines are missing. Immediate distribution maintains high impact, whereas delaying treatment by one to five days cuts saved lives by nearly half.